<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000301806"><SummaryMetaData><SummaryType>Complementary and alternative medicine</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the use of Essiac/Flor Essence as a treatment for  people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only.</SummaryDescription><SummaryURL xref="http://cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq">Essiac/Flor Essence (PDQ®)</SummaryURL><MainTopics><TermRef ref="CDR0000304440">Essiac</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Essiac/Flor Essence (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Essiac/Flor Essence</AltTitle><SummarySection id="_1"><Title>Overview</Title><Para id="_104"><Strong>NOTE: The information in this summary is no longer being updated and is provided for reference purposes only.</Strong></Para><Para id="_2">This <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> (CAM) information summary provides an overview of the use of <GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef> and Flor Essence, which are proprietary <GlossaryTermRef href="CDR0000463714">herbal</GlossaryTermRef> tea mixtures, as treatments  for people with <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>. The summary includes a brief history of the development of Essiac and Flor Essence; a review of <GlossaryTermRef href="CDR0000044512">laboratory</GlossaryTermRef>, <GlossaryTermRef href="CDR0000454774">animal</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044195">human studies</GlossaryTermRef>; and possible <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef> associated with Essiac and Flor Essence use. </Para><Para id="_3">This summary contains the following key information:</Para><ItemizedList id="_4" Style="bullet"><ListItem>Essiac and Flor Essence are herbal tea mixtures originally developed in Canada. There may be differences between Essiac and Flor Essence in their mixture content and effects.</ListItem><ListItem>These products are marketed worldwide as <GlossaryTermRef href="CDR0000373932">dietary supplements</GlossaryTermRef>.</ListItem><ListItem>Proponents have claimed that Essiac and Flor Essence can help <GlossaryTermRef href="CDR0000446105">detoxify</GlossaryTermRef> the body,  strengthen the <GlossaryTermRef href="CDR0000046356">immune system</GlossaryTermRef>, and fight cancer.</ListItem><ListItem>Proponents of Essiac have further claimed  that it can help relieve pain, reduce side effects, improve <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef>, and reduce tumor size.</ListItem><ListItem><GlossaryTermRef href="CDR0000045065">Molecules</GlossaryTermRef> with <GlossaryTermRef href="CDR0000043997">antioxidant</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044187">anti-inflammatory</GlossaryTermRef>, anticancer, or <GlossaryTermRef href="CDR0000285968">immunostimulatory</GlossaryTermRef> activity have been identified in the individual herbs in the Essiac and Flor Essence formulas.</ListItem><ListItem>No controlled data are available from  human studies to suggest that Essiac or Flor Essence can be effective in the treatment of patients with cancer. </ListItem><ListItem>Some evidence suggests that  Flor Essence may increase tumor formation in an animal model of breast cancer.</ListItem></ItemizedList><Para id="_5">Many of the medical and scientific terms used in the summary are hypertext linked (at first use in each section) to the <ExternalRef xref="http://www.cancer.gov/dictionary/">NCI Dictionary of Cancer Terms</ExternalRef>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. </Para><Para id="_6">Reference citations in some <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> CAM information summaries may include links to external Web sites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the Web sites, or of any treatment or product, by the PDQ Cancer CAM Editorial Board or the <GlossaryTermRef href="CDR0000044266">National Cancer Institute</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_7"><Title>General Information</Title><Para id="_8"><GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef> and Flor Essence are proprietary <GlossaryTermRef href="CDR0000463714">herbal</GlossaryTermRef> tea mixtures produced by different manufacturers. Essiac is reported to contain four herbs: <GlossaryTermRef href="CDR0000330164">burdock</GlossaryTermRef> root (<ScientificName>Arctium lappa</ScientificName> L.), <GlossaryTermRef href="CDR0000330194">Indian rhubarb</GlossaryTermRef> root (<ScientificName>Rheum palmatum</ScientificName> L., sometimes known as Turkish rhubarb), <GlossaryTermRef href="CDR0000330179">sheep sorrel</GlossaryTermRef> (<ScientificName>Rumex acetosella</ScientificName> L.),  and the inner bark of <GlossaryTermRef href="CDR0000330180">slippery elm</GlossaryTermRef> (<ScientificName>Ulmus fulva</ScientificName> Michx.  [synonym <ScientificName>Ulmus rubra</ScientificName>]).<Reference refidx="1"/>    <Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/>
     Flor Essence is reported to contain the same four herbs as Essiac, plus four <GlossaryTermRef href="CDR0000330176">potentiating</GlossaryTermRef> herbs: <GlossaryTermRef href="CDR0000330181">watercress</GlossaryTermRef> (<ScientificName>Nasturtium officinale</ScientificName> R.Br.),  <GlossaryTermRef href="CDR0000330162">blessed thistle</GlossaryTermRef> (<ScientificName>Cnicus benedictus</ScientificName> L.),  <GlossaryTermRef href="CDR0000330178">red clover</GlossaryTermRef> (<ScientificName>Trifolium pratense</ScientificName> L.), and <GlossaryTermRef href="CDR0000330171">kelp</GlossaryTermRef> (<ScientificName>Laminaria digitata</ScientificName> [Hudson] Lamx.).<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="10"/></Para><Para id="_11">The manufacturers of Essiac and Flor Essence both claim they market the original herbal mixture promoted by the developer.<Reference refidx="1"/><Reference refidx="10"/> Although only one company manufactures Flor Essence,<Reference refidx="10"/> several companies produce and market Essiac-like products.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="9"/>  This summary contains information about the trademarked mixtures only and differentiates between the two products wherever possible. Essiac and Flor Essence may vary in their mixture content and effects.<Reference refidx="11"/></Para><Para id="_12">Essiac and Flor Essence are said to <GlossaryTermRef href="CDR0000446105">detoxify</GlossaryTermRef> the body and strengthen the <GlossaryTermRef href="CDR0000046356">immune system</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="4"/><Reference refidx="6"/><Reference refidx="8"/><Reference refidx="10"/>  Proponents of Essiac further claim  that it helps relieve pain, reduce side effects, improves overall <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef>, may reduce tumor size, and may prolong the survival of patients with various types of <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>.  The individual herbs in the Essiac and Flor Essence formulas have been shown to contain <GlossaryTermRef href="CDR0000045065">molecules</GlossaryTermRef> that have anticancer, <GlossaryTermRef href="CDR0000044187">anti-inflammatory</GlossaryTermRef>, <GlossaryTermRef href="CDR0000043997">antioxidant</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000285968">immunostimulatory</GlossaryTermRef> activity (refer to the <SummaryRef href="CDR0000301806#_27" url="/about-cancer/treatment/cam/hp/essiac-pdq">Laboratory/Animal/Preclinical Studies</SummaryRef> section of this summary for more information).<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="8"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/>   It is said that the benefits of Essiac and Flor Essence are dependent on the presence of the constituent herbs in the correct proportions. In 2004, a mixture of the Essiac herbs showed a decreased proliferation of a <GlossaryTermRef href="CDR0000445079">prostate cancer</GlossaryTermRef> cell line.<Reference refidx="16"/> (Refer to the <SummaryRef href="CDR0000301806#_27" url="/about-cancer/treatment/cam/hp/essiac-pdq">Laboratory/Animal/Preclinical Studies</SummaryRef> section of this summary for more information.)</Para><Para id="_13">Although the use of Essiac and Flor Essence is generally associated with cancer treatment, both products have been used to treat other health conditions. Essiac has reportedly been used to control <GlossaryTermRef href="CDR0000044911">diabetes</GlossaryTermRef> and to treat <GlossaryTermRef href="CDR0000044365">acquired immunodeficiency syndrome</GlossaryTermRef>.<Reference refidx="6"/> Flor Essence has reportedly been studied in Russia as a treatment for <GlossaryTermRef href="CDR0000045641">chronic</GlossaryTermRef> <GlossaryTermRef href="CDR0000045692">gastrointestinal</GlossaryTermRef> diseases (e.g., <GlossaryTermRef href="CDR0000044947">esophagitis</GlossaryTermRef>, <GlossaryTermRef href="CDR0000330169">gastritis</GlossaryTermRef>, <GlossaryTermRef href="CDR0000330166">duodenitis</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000044318">colitis</GlossaryTermRef>) and as a treatment for <GlossaryTermRef href="CDR0000045478">cirrhosis</GlossaryTermRef> of the <GlossaryTermRef href="CDR0000046312">liver</GlossaryTermRef>.<Reference refidx="2"/> However, no controlled data have been published in the peer-reviewed scientific literature to show the safety or the efficacy of Essiac or Flor Essence in patients with cancer or in patients with other health conditions (refer to the  <SummaryRef href="CDR0000301806#_39" url="/about-cancer/treatment/cam/hp/essiac-pdq">Human/Clinical Studies</SummaryRef> section  of this summary for more information).</Para><Para id="_14">Essiac and Flor Essence are sold worldwide as health tonics or herbal <GlossaryTermRef href="CDR0000373932">dietary supplements</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="10"/> <Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="9"/>   In the United States, health tonics and dietary supplements are regulated as foods, not drugs. Therefore, premarket evaluation and approval by the <GlossaryTermRef href="CDR0000454785">U.S. Food and Drug Administration</GlossaryTermRef> (FDA) are not required, and specific disease treatment or prevention claims are not allowed. Because health tonics and dietary supplements are not formally inspected for manufacturing consistency, there may be considerable variation from lot to lot, and there is no guarantee that ingredients identified on product labels are present at all or are present in the specified amounts. The FDA has not approved the use of either Essiac or Flor Essence for the treatment of patients with cancer or any other medical condition.</Para><Para id="_15">To conduct <GlossaryTermRef href="CDR0000044195">clinical</GlossaryTermRef> drug research in the United States, researchers must file an <GlossaryTermRef href="CDR0000762975">Investigational New Drug</GlossaryTermRef> (IND) application with the FDA. An IND application must also be made for clinical evaluation of dietary supplements as agents for the treatment or prevention of disease. The FDA’s IND process is confidential, and the existence of an IND application can be disclosed only by the applicants. To date, no <GlossaryTermRef href="CDR0000044685">investigator</GlossaryTermRef> has announced filing an IND application to study either Essiac or Flor Essence in the treatment of patients with cancer.</Para><Para id="_16">Essiac and Flor Essence are administered <GlossaryTermRef href="CDR0000044068">orally</GlossaryTermRef> in the form of herbal teas.<Reference refidx="1"/><Reference refidx="4"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="10"/><Reference refidx="17"/>  Originally, an extract of one of the herbs (not specified) was administered to cancer patients by <GlossaryTermRef href="CDR0000044049">intramuscular injection</GlossaryTermRef> at or near tumor sites, and the other herbs were administered orally as a tea.</Para><Para id="_17">Only minimal information about <GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> and schedule of administration is freely available from the manufacturer of Essiac.<Reference refidx="1"/>   According to the manufacturer, the dose will vary, depending on the reason for <GlossaryTermRef href="CDR0000044100">ingestion</GlossaryTermRef>;  the manufacturer’s recommended schedules of administration assume a 12-week program of uninterrupted use.<Reference refidx="1"/>   Although Essiac is said to be safe for pets, no information is given about its safety in children.<Reference refidx="1"/></Para><Para id="_18">The manufacturer of Flor Essence states that adults may consume from 30 to 360 <GlossaryTermRef href="CDR0000044214">mL</GlossaryTermRef> (i.e., 1–12 <GlossaryTermRef href="CDR0000044669">fl</GlossaryTermRef> <GlossaryTermRef href="CDR0000330174">oz</GlossaryTermRef>) of Flor Essence tea per day, depending on individual requirements, and that it may be used continuously.<Reference refidx="10"/>  The manufacturer also suggests that Flor Essence may be safely consumed by infants and children, but its use by pregnant women and nursing mothers is not recommended.<Reference refidx="10"/> However, the promotion of mammary tumors observed in a rat model of breast cancer raises the theoretical concern that Flor Essence may impact normal mammary ductal development during childhood, thereby raising concern about its use.<Reference refidx="18"/></Para><Para id="_19">The manufacturers of Essiac and Flor Essence both state these products can be used in conjunction with other cancer treatments.<Reference refidx="1"/><Reference refidx="10"/>   Nonetheless, some proponents of Essiac have recommended that no additional anticancer therapy (such as <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef> or <GlossaryTermRef href="CDR0000044971">radiation therapy</GlossaryTermRef>) be undertaken while patients are being treated with the mixture.<Reference refidx="7"/> The purported rationale for this statement is that <GlossaryTermRef href="CDR0000044950">conventional</GlossaryTermRef> anticancer treatments may alter immune system function and prevent Essiac from working effectively.<Reference refidx="7"/>  As indicated previously, no evidence has been reported in the peer-reviewed scientific literature to show either that Essiac is an effective treatment for patients with cancer or that conventional anticancer treatments interfere with its effects.</Para><ReferenceSection><Citation idx="1">Essiac. Kirkland, Canada: Altramed Health Products, 2002. <ExternalRef xref="http://www.essiac-resperin.com/">Available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="2" PMID="10641040" MedlineID="20109238">Tamayo C, Richardson MA, Diamond S, et al.: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 14 (1): 1-14, 2000.</Citation><Citation idx="3">Tamayo C: Essiac for cancer. Alternative Therapies in Women's Health  2 (3): 19-23, 2000.</Citation><Citation idx="4" PMID="9559016" MedlineID="98219770">Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (7): 897-902, 1998.</Citation><Citation idx="5" PMID="10673970" MedlineID="20138925">Ernst E, Cassileth BR: How useful are unconventional cancer treatments? Eur J Cancer 35 (11): 1608-13, 1999.</Citation><Citation idx="6">Locock RA: Essiac. Can Pharm J  130: 18-9, 1997.</Citation><Citation idx="7">Herbal treatments. In: US Congress, Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC: U.S. Government Printing Office, 1990. OTA-H-405, pp 71-5. <ExternalRef xref="http://www.princeton.edu/~ota/disk2/1990/9044_n.html">Also available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="8">Essiac. Toronto, Canada: Canadian Breast Cancer Research Alliance, 1996.</Citation><Citation idx="9">The History of Essiac &amp; Rene Caisse, Canada's Cancer Nurse. Kirkland, Canada: Altramed Health Products, 2001. <ExternalRef xref="http://www.essiacinfo.org/">Available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="10">Flora Flor•Essence®. Burnaby, Canada: Flora Manufacturing &amp; Distributing Ltd. <ExternalRef xref="http://www.florahealth.com/product_categories_usa.cfm"> Available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="11" PMID="16211307">Cheung S, Lim KT, Tai J: Antioxidant and anti-inflammatory properties of ESSIAC and Flor-Essence. Oncol Rep 14 (5): 1345-50, 2005.</Citation><Citation idx="12">Franke AA, Cooney RV, Custer LJ, et al.: Inhibition of neoplastic transformation and bioavailability of dietary flavonoid agents. In: Manthey JA, Buslig BS, eds.: Flavonoids in the Living System. New York, NY: Plenum Press, 1998. Advances in Experimental Medicine and Biology, 439, pp 237-48.</Citation><Citation idx="13" PMID="9852292" MedlineID="99074484">Waladkhani AR, Clemens MR: Effect of dietary phytochemicals on cancer development (review) Int J Mol Med 1 (4): 747-53, 1998.</Citation><Citation idx="14" PMID="8234447" MedlineID="94052327">de Witte P: Metabolism and pharmacokinetics of anthranoids. Pharmacology 47 (Suppl 1): 86-97, 1993.</Citation><Citation idx="15" PMID="12553004" MedlineID="22441170">Campbell MJ, Hamilton B, Shoemaker M, et al.: Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 22 (6C): 3843-52, 2002 Nov-Dec.</Citation><Citation idx="16" PMID="15353028">Ottenweller J, Putt K, Blumenthal EJ, et al.: Inhibition of prostate cancer-cell proliferation by Essiac. J Altern Complement Med 10 (4): 687-91, 2004.</Citation><Citation idx="17" PMID="9450419" MedlineID="98112218">LeMoine L: Essiac: an historical perspective. Can Oncol Nurs J 7 (4): 216-21, 1997.</Citation><Citation idx="18" PMID="15538049">Bennett LM, Montgomery JL, Steinberg SM, et al.: Flor-Essence herbal tonic does not inhibit mammary tumor development in Sprague Dawley rats. Breast Cancer Res Treat 88 (1): 87-93, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_9"><Title>History</Title><Para id="_10"><GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef> was popularized in Canada during the 1920s, when the developer, a nurse from Ontario, began to advocate its use as a <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> treatment. In 1922, the developer obtained an herbal tea formula from a female breast cancer patient who claimed the mixture had cured her disease.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>   The patient reportedly received the formula from an Ontario Ojibwa Native American medicine man. The developer subsequently modified the formula, producing both <GlossaryTermRef href="CDR0000044678">injectable</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef> forms of treatment.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_20">From 1934 to 1942, the developer operated a cancer clinic in Bracebridge, Ontario, and dispensed Essiac free of charge.<Reference refidx="9"/>  In 1938, members of the Royal Cancer Commission of Canada visited the clinic and heard testimonials from patients who had been treated with the mixture.<Reference refidx="7"/>  The Cancer Commission concluded there was only limited evidence for the effectiveness of Essiac. After years of controversy, the developer closed the clinic in 1942 but continued to provide Essiac to patients until the late 1970s.<Reference refidx="4"/>  (Refer to  the <SummaryRef href="CDR0000301806#_39" url="/about-cancer/treatment/cam/hp/essiac-pdq">Human/Clinical Studies</SummaryRef> section of this summary for more information.)</Para><Para id="_21">From 1959 until the late 1970s, the developer collaborated with an American physician to conduct <GlossaryTermRef href="CDR0000044195">clinical</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044512">laboratory studies</GlossaryTermRef> of Essiac and to promote its use.<Reference refidx="7"/>   This collaboration led to the development of the eight-herb formula now marketed as Flor Essence. None of the results of these collaborative studies were reported in peer-reviewed scientific journals.</Para><Para id="_22">In 1977, the developer provided a four-herb recipe for Essiac to a Canadian corporation.<Reference refidx="5"/><Reference refidx="7"/>   In 1978, the corporation filed a preclinical new drug submission with the Canadian Department of National Health and Welfare (Health Protection Branch) and received permission to conduct clinical studies of Essiac’s safety and effectiveness in cancer patients.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="7"/><Reference refidx="8"/> In 1982, this permission was withdrawn when it was determined that the corporation had not fulfilled commitments to adequately control the manufacturing consistency of Essiac, to isolate and characterize active substances in the mixture, and to design and execute appropriate <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef>.<Reference refidx="4"/><Reference refidx="5"/>   During this period, restrictions were imposed on the promotion of Essiac as a cancer treatment, but the corporation was allowed to distribute it to cancer patients through their physicians under Canada’s Emergency Drug Release Program (also called Health Canada’s Special Access Programme).<Reference refidx="7"/>  While the preclinical new drug submission was in effect in Canada, the corporation filed an unsuccessful New Drug Application (NDA) with the <GlossaryTermRef href="CDR0000454785">U.S. Food and Drug Administration</GlossaryTermRef>, seeking permission to market Essiac in the United States. Details of the NDA submission, which can be disclosed only by the corporation, have not been made public.<Reference refidx="4"/>  (Refer to the <SummaryRef href="CDR0000301806#_39" url="/about-cancer/treatment/cam/hp/essiac-pdq">Human/Clinical Studies</SummaryRef> section of this summary for more information.)</Para><Para id="_23">In the early 1980s, the Canadian Department of National Health and Welfare (Bureau of Human Prescription Drugs) conducted a <GlossaryTermRef href="CDR0000044120">retrospective</GlossaryTermRef> review of case summaries submitted by physicians whose patients had obtained Essiac under the Emergency Drug Release Program.<Reference refidx="2"/><Reference refidx="4"/><Reference refidx="7"/>  The Department found little evidence to suggest that Essiac was effective as a cancer treatment. (Refer to the <SummaryRef href="CDR0000301806#_39" url="/about-cancer/treatment/cam/hp/essiac-pdq">Human/Clinical Studies</SummaryRef> section of this summary for more information.)</Para><Para id="_24">Also in the 1980s, the manufacturers of Essiac-like products began to market their formulations as health tonics and to avoid making claims of effectiveness in treating disease. Consequently, the mixtures were no longer subject to regulation as drugs.    Essiac is not currently available under Canada’s Emergency Drug Release Program.</Para><Para id="_25">In 1995, the corporation that acquired the four-herb recipe for Essiac from the developer dissolved voluntarily.<Reference refidx="1"/>   Later that year, a new company was formed to manufacture and distribute this proprietary herbal mixture.<Reference refidx="1"/><Reference refidx="5"/></Para><ReferenceSection><Citation idx="1">Essiac. Kirkland, Canada: Altramed Health Products, 2002. <ExternalRef xref="http://www.essiac-resperin.com/">Available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="2">Tamayo C: Essiac for cancer. Alternative Therapies in Women's Health  2 (3): 19-23, 2000.</Citation><Citation idx="3">Locock RA: Essiac. Can Pharm J  130: 18-9, 1997.</Citation><Citation idx="4">Herbal treatments. In: US Congress, Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC: U.S. Government Printing Office, 1990. OTA-H-405, pp 71-5. <ExternalRef xref="http://www.princeton.edu/~ota/disk2/1990/9044_n.html">Also available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="5" PMID="9450419" MedlineID="98112218">LeMoine L: Essiac: an historical perspective. Can Oncol Nurs J 7 (4): 216-21, 1997.</Citation><Citation idx="6" PMID="10641040" MedlineID="20109238">Tamayo C, Richardson MA, Diamond S, et al.: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 14 (1): 1-14, 2000.</Citation><Citation idx="7" PMID="9559016" MedlineID="98219770">Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (7): 897-902, 1998.</Citation><Citation idx="8">Essiac. Toronto, Canada: Canadian Breast Cancer Research Alliance, 1996.</Citation><Citation idx="9">The History of Essiac &amp; Rene Caisse, Canada's Cancer Nurse. Kirkland, Canada: Altramed Health Products, 2001. <ExternalRef xref="http://www.essiacinfo.org/">Available online</ExternalRef>. Last accessed May 21, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_27"><Title>Laboratory/Animal/Preclinical Studies</Title><SummarySection id="_28"><Title>Essiac</Title><Para id="_29">In 2004, a mixture of the <GlossaryTermRef href="CDR0000446524">Essiac </GlossaryTermRef> herbs showed a decreased proliferation in a <GlossaryTermRef href="CDR0000445079">prostate cancer</GlossaryTermRef> <GlossaryTermRef href="CDR0000695994">cell line</GlossaryTermRef>.<Reference refidx="1"/> Results of laboratory (<Emphasis>in vitro</Emphasis>) studies of Essiac have been reported.<Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_30">In the mid-1970s, the developer submitted both dried and liquid samples of Essiac to the Memorial Sloan Kettering Cancer Center (MSKCC) in New York City for evaluation of its <GlossaryTermRef href="CDR0000045729">immunotherapeutic</GlossaryTermRef> and <GlossaryTermRef href="CDR0000044009">chemotherapeutic</GlossaryTermRef> potential.<Reference refidx="3"/> No <GlossaryTermRef href="CDR0000285968">immunostimulatory</GlossaryTermRef> or chemotherapeutic activity was detected in eight animal experiments that utilized the S-180 mouse <GlossaryTermRef href="CDR0000045562">sarcoma</GlossaryTermRef> <GlossaryTermRef href="CDR0000044091">tumor model</GlossaryTermRef>.</Para><Para id="_55">In the early 1980s, the corporation that acquired the four-herb recipe for Essiac from the developer submitted another sample to the MSKCC for evaluation in additional <GlossaryTermRef href="CDR0000454774">animal studies</GlossaryTermRef>. No anticancer activity was detected in 17 separate experiments that utilized a variety of animal <GlossaryTermRef href="CDR0000045343">leukemia</GlossaryTermRef> and tumor models.<Reference refidx="3"/></Para><Para id="_56">In 1983, the <GlossaryTermRef href="CDR0000044266">National Cancer Institute</GlossaryTermRef> tested a liquid sample of Essiac that was provided by the manufacturer after the Canadian Department of National Health and Welfare (Health Protection Branch) requested that it be tested in animals.<Reference refidx="3"/> These studies revealed no anticancer activity in the mouse P388 <GlossaryTermRef href="CDR0000330173">lymphocytic  leukemia</GlossaryTermRef> tumor system and found lethal <GlossaryTermRef href="CDR0000043986">toxicity</GlossaryTermRef> at the highest concentrations of Essiac administered to test animals. It is not known, however, how the concentrations used in these animal tests compare with the concentrations achieved in humans after the consumption of the manufacturer's recommended <GlossaryTermRef href="CDR0000044664">doses</GlossaryTermRef>. </Para></SummarySection><SummarySection id="_32"><Title>Flor Essence</Title><Para id="_33"> There are conflicting results in the peer-reviewed literature. One study suggests that Flor Essence enhances tumor growth <Emphasis>in vitro</Emphasis>, a finding that contradicts the widely available <GlossaryTermRef href="CDR0000043995">anecdotal</GlossaryTermRef> evidence that this product suppresses or inhibits tumor development.<Reference refidx="4"/> Another study suggests that the growth of human <GlossaryTermRef href="CDR0000444971">breast cancer</GlossaryTermRef> cells is stimulated through <GlossaryTermRef href="CDR0000046409">estrogen receptor</GlossaryTermRef> (ER)–mediated as well as ER-independent mechanisms of action from  Flor Essence and Essiac herbal tonics.<Reference refidx="5"/> A third study demonstrated antiproliferative and differentiation-inducing properties <Emphasis>in vitro</Emphasis> only in high concentrations of   Essiac and Flor Essence herbal teas.<Reference refidx="6"/></Para><Para id="_79">The 2004 <Emphasis>in vivo</Emphasis> study of Flor Essence in a rat model looked at <GlossaryTermRef href="CDR0000044560">mammary</GlossaryTermRef> tumor development following administration of the herbal compound.  Sprague-Dawley rats (N = 112) were assigned to one of three groups. The control group (n = 35)  received water only. The second group (n = 40) received 3% Flor Essence in their drinking water in an attempt to provide a dose equivalent to that recommended in the popular literature. The third group (n = 37) received 6% Flor Essence in their drinking water to investigate the dose-response relationship. Mammary tumors were induced by a 40 mg/kg of body weight dose of 7,12-dimethylbenz(a)anthracene. At 19 weeks, palpable mammary tumor incidence was higher (65% and 59.4%) in both Flor Essence groups, compared with controls (51%). Terminal necropsy was performed at age 23 weeks  or when tumor burden became too great. Results showed mammary tumor incidence was 82.5% for controls, compared with 90% and 97.3%, respectively, for rats consuming 3% and 6% Flor Essence.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_34"><Title>The Individual Herbs of Essiac and Flor Essence</Title><Para id="_35">Laboratory and animal experiments have shown that some of the chemicals in the herbs used to make Essiac and Flor Essence have <GlossaryTermRef href="CDR0000043997">antioxidant</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044187">anti-inflammatory</GlossaryTermRef>, estrogenic,  or anticancer activity.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/> <Reference refidx="14"/><Reference refidx="15"/></Para><Para id="_36">Among the herbs used in both mixtures, <GlossaryTermRef href="CDR0000330164">burdock</GlossaryTermRef> root (<ScientificName>Arctium lappa</ScientificName> L.) contains several <GlossaryTermRef href="CDR0000330168">flavonoids</GlossaryTermRef> and <GlossaryTermRef href="CDR0000256573">polyphenols</GlossaryTermRef> that have shown antioxidant activity; <GlossaryTermRef href="CDR0000330194">Indian rhubarb</GlossaryTermRef> root  (<ScientificName>Rheum palmatum</ScientificName> L.) contains several <GlossaryTermRef href="CDR0000045595">anthraquinones</GlossaryTermRef>, including <GlossaryTermRef href="CDR0000330167">emodin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000330159">aloe-emodin</GlossaryTermRef>, which have demonstrated anti-inflammatory and <GlossaryTermRef href="CDR0000044020">cytotoxic</GlossaryTermRef> effects; <GlossaryTermRef href="CDR0000330179">sheep sorrel</GlossaryTermRef> (<ScientificName>Rumex acetosella</ScientificName> L.) contains several types of anthraquinones, including emodin and aloe-emodin, as well as <GlossaryTermRef href="CDR0000330175">phytoestrogens</GlossaryTermRef>, which may possess both procancer and anticancer activity; and <GlossaryTermRef href="CDR0000330180">slippery elm</GlossaryTermRef> bark (<ScientificName>Ulmus fulva</ScientificName> Michx.) has been shown to contain  antioxidants.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/></Para><Para id="_37">Among the herbs found in Flor Essence alone, <GlossaryTermRef href="CDR0000330181">watercress</GlossaryTermRef> (<ScientificName>Nasturtium officinale</ScientificName> R.Br.) contains <GlossaryTermRef href="CDR0000044910">phenethyl isothiocyanate</GlossaryTermRef> (PEITC), which has shown cytotoxic and antitumor activities; <GlossaryTermRef href="CDR0000330162">blessed thistle</GlossaryTermRef>  (<ScientificName>Cnicus benedictus</ScientificName> L.) contains <GlossaryTermRef href="CDR0000330165">cnicin</GlossaryTermRef>, which is a <GlossaryTermRef href="CDR0000330182">sesquiterpene lactone</GlossaryTermRef> that has demonstrated cytotoxic, antitumor, and anti-inflammatory effects, and <GlossaryTermRef href="CDR0000330161">arctiin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000330160">arctigenin</GlossaryTermRef>, which are <GlossaryTermRef href="CDR0000330172">lignans</GlossaryTermRef> that have shown anticancer activity; <GlossaryTermRef href="CDR0000330178">red clover</GlossaryTermRef> (<ScientificName>Trifolium pratense</ScientificName> L.) contains a complex mixture of phytoestrogens, including <GlossaryTermRef href="CDR0000046107">genistein</GlossaryTermRef>, which has demonstrated <GlossaryTermRef href="CDR0000044186">antiangiogenic</GlossaryTermRef>, estrogenic,  and procancer and anticancer effects (depending on the dose); and  extracts of <GlossaryTermRef href="CDR0000330171">kelp</GlossaryTermRef> (<ScientificName>Laminaria digitata</ScientificName> [Hudson] Lamx.) have shown immunostimulatory and antitumor activities.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="15"/></Para><Para id="_38">Whether equivalent concentrations of relevant <GlossaryTermRef href="CDR0000045065">molecules</GlossaryTermRef> can be achieved in the bloodstream of individuals who consume Essiac or Flor Essence in the amounts recommended by their manufacturers has not been determined. An uncharacterized Flor Essence commercial product was dosed at amounts lower than those recommended by the manufacturers for humans, and there was an increase in tumor incidence in this model.<Reference refidx="4"/> </Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15353028">Ottenweller J, Putt K, Blumenthal EJ, et al.: Inhibition of prostate cancer-cell proliferation by Essiac. J Altern Complement Med 10 (4): 687-91, 2004.</Citation><Citation idx="2" PMID="18225545">Seely D, Kennedy DA, Myers SP, et al.: In vitro analysis of the herbal compound Essiac. Anticancer Res 27 (6B): 3875-82, 2007 Nov-Dec.</Citation><Citation idx="3">Herbal treatments. In: US Congress, Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC: U.S. Government Printing Office, 1990. OTA-H-405, pp 71-5. <ExternalRef xref="http://www.princeton.edu/~ota/disk2/1990/9044_n.html">Also available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="4" PMID="15538049">Bennett LM, Montgomery JL, Steinberg SM, et al.: Flor-Essence herbal tonic does not inhibit mammary tumor development in Sprague Dawley rats. Breast Cancer Res Treat 88 (1): 87-93, 2004.</Citation><Citation idx="5" PMID="16541326">Kulp KS, Montgomery JL, Nelson DO, et al.: Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Res Treat 98 (3): 249-59, 2006.</Citation><Citation idx="6" PMID="14719086">Tai J, Cheung S, Wong S, et al.: In vitro comparison of Essiac and Flor-Essence on human tumor cell lines. Oncol Rep 11 (2): 471-6, 2004.</Citation><Citation idx="7" PMID="10641040" MedlineID="20109238">Tamayo C, Richardson MA, Diamond S, et al.: The chemistry and biological activity of herbs used in Flor-Essence herbal tonic and Essiac. Phytother Res 14 (1): 1-14, 2000.</Citation><Citation idx="8">Tamayo C: Essiac for cancer. Alternative Therapies in Women's Health  2 (3): 19-23, 2000.</Citation><Citation idx="9" PMID="9559016" MedlineID="98219770">Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (7): 897-902, 1998.</Citation><Citation idx="10">Essiac. Toronto, Canada: Canadian Breast Cancer Research Alliance, 1996.</Citation><Citation idx="11">Franke AA, Cooney RV, Custer LJ, et al.: Inhibition of neoplastic transformation and bioavailability of dietary flavonoid agents. In: Manthey JA, Buslig BS, eds.: Flavonoids in the Living System. New York, NY: Plenum Press, 1998. Advances in Experimental Medicine and Biology, 439, pp 237-48.</Citation><Citation idx="12" PMID="9852292" MedlineID="99074484">Waladkhani AR, Clemens MR: Effect of dietary phytochemicals on cancer development (review) Int J Mol Med 1 (4): 747-53, 1998.</Citation><Citation idx="13" PMID="8234447" MedlineID="94052327">de Witte P: Metabolism and pharmacokinetics of anthranoids. Pharmacology 47 (Suppl 1): 86-97, 1993.</Citation><Citation idx="14" PMID="12553004" MedlineID="22441170">Campbell MJ, Hamilton B, Shoemaker M, et al.: Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 22 (6C): 3843-52, 2002 Nov-Dec.</Citation><Citation idx="15" PMID="12670155" MedlineID="22557758">Boué SM, Wiese TE, Nehls S, et al.: Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem 51 (8): 2193-9, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_39"><Title>Human/Clinical Studies</Title><SummarySection id="_40"><Title>Essiac</Title><Para id="_41">No report of a <GlossaryTermRef href="CDR0000044195">clinical study</GlossaryTermRef> of <GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef> has been published in the peer-reviewed scientific literature. Brief descriptions of one incomplete clinical study and one <GlossaryTermRef href="CDR0000044120">retrospective</GlossaryTermRef> evaluation of Essiac as a treatment for <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> have been published.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/>  It is not clear whether the described patient populations consisted entirely of adults or whether they included children.</Para><Para id="_42">As noted previously (refer to the <SummaryRef href="CDR0000301806#_9" url="/about-cancer/treatment/cam/hp/essiac-pdq">History</SummaryRef> section of this summary for more information), the developer provided a four-herb recipe for  Essiac to a Canadian corporation in 1977.<Reference refidx="2"/><Reference refidx="6"/> In 1978, the corporation filed a preclinical new drug submission with the Canadian Department of National Health and Welfare (Health Protection Branch) and received permission to conduct studies on   the safety and the <GlossaryTermRef href="CDR0000346517">efficacy</GlossaryTermRef> of Essiac in cancer patients.<Reference refidx="2"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> <Reference refidx="7"/>   In 1982, the Department withdrew its permission after determining the research was not being conducted as planned (refer to the <SummaryRef href="CDR0000301806#_9" url="/about-cancer/treatment/cam/hp/essiac-pdq">History</SummaryRef> section of this summary for more information).   At that time, the available incomplete data were reviewed, and no clear evidence of improved survival could be demonstrated for treated patients.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="5"/><Reference refidx="6"/> Pain control and <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef> were not assessed in these studies. The review of the data indicated, however, that Essiac was not <GlossaryTermRef href="CDR0000043986">toxic</GlossaryTermRef>. Because no evidence of harm was found, the Canadian government allowed the corporation to distribute Essiac to cancer patients through their physicians under Canada’s Emergency Drug Release Program. Nonetheless, restrictions were imposed on the promotion of Essiac as a treatment for cancer.<Reference refidx="2"/> Access to Essiac under Canada’s Emergency Drug Release Program has since been discontinued.</Para><Para id="_43">In the early 1980s, the Canadian Department of National Health and Welfare (Bureau of Human Prescription Drugs) conducted a retrospective review of data voluntarily submitted by physicians for 86 cancer patients who had obtained Essiac under Canada’s Emergency Drug Release Program between 1978 and 1982.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="4"/> (Note: <Reference refidx="2"/>    states that data from 87 patients were reviewed.) The Bureau’s evaluation was based on written summaries submitted by the physicians and not on a review of the original patient records.<Reference refidx="4"/> The Bureau found 47 patients who did not benefit from Essiac; 1 had <GlossaryTermRef href="CDR0000330183">subjective improvement</GlossaryTermRef>, 5 required fewer <GlossaryTermRef href="CDR0000045590">analgesics</GlossaryTermRef>, 4 had an <GlossaryTermRef href="CDR0000044067">objective response</GlossaryTermRef>, and four were in stable condition.<Reference refidx="1"/><Reference refidx="4"/> Among the remaining 25 patients, 17 had died, and the reports for 8 were considered unevaluable. The Bureau solicited additional information about the four patients who had an objective response and the four patients who were in stable condition. This additional information revealed that, among these eight patients, two had died, three had <GlossaryTermRef href="CDR0000045850">progressive disease</GlossaryTermRef>, and three remained in stable condition.<Reference refidx="1"/><Reference refidx="4"/> The three patients in stable condition had received previous <GlossaryTermRef href="CDR0000044198">conventional therapy</GlossaryTermRef>. Therefore, the benefits of treatment for these patients, if any, could not be clearly ascribed to Essiac.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_44"><Title>Flor Essence</Title><Para id="_45">No results of human studies of Flor Essence have been reported <GlossaryTermRef href="CDR0000043995">anecdotally</GlossaryTermRef> or in the peer-reviewed scientific literature.</Para></SummarySection><ReferenceSection><Citation idx="1">Tamayo C: Essiac for cancer. Alternative Therapies in Women's Health  2 (3): 19-23, 2000.</Citation><Citation idx="2" PMID="9559016" MedlineID="98219770">Kaegi E: Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (7): 897-902, 1998.</Citation><Citation idx="3">Locock RA: Essiac. Can Pharm J  130: 18-9, 1997.</Citation><Citation idx="4">Herbal treatments. In: US Congress, Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC: U.S. Government Printing Office, 1990. OTA-H-405, pp 71-5. <ExternalRef xref="http://www.princeton.edu/~ota/disk2/1990/9044_n.html">Also available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="5">Essiac. Toronto, Canada: Canadian Breast Cancer Research Alliance, 1996.</Citation><Citation idx="6" PMID="9450419" MedlineID="98112218">LeMoine L: Essiac: an historical perspective. Can Oncol Nurs J 7 (4): 216-21, 1997.</Citation><Citation idx="7" PMID="12553004" MedlineID="22441170">Campbell MJ, Hamilton B, Shoemaker M, et al.: Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro. Anticancer Res 22 (6C): 3843-52, 2002 Nov-Dec.</Citation></ReferenceSection></SummarySection><SummarySection id="_46"><Title>Adverse Effects</Title><Para id="_47"><GlossaryTermRef href="CDR0000390302">Nausea</GlossaryTermRef> and <GlossaryTermRef href="CDR0000390324">vomiting</GlossaryTermRef> are the only reported <GlossaryTermRef href="CDR0000044922">adverse effects</GlossaryTermRef> associated with the use of <GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef>.<Reference refidx="1"/> The manufacturer of Flor Essence states that users may experience increased bowel movements, frequent urination, swollen glands, skin blemishes, flu-like symptoms, or slight headaches.<Reference refidx="2"/> </Para><ReferenceSection><Citation idx="1">Herbal treatments. In: US Congress, Office of Technology Assessment: Unconventional Cancer Treatments. Washington, DC: U.S. Government Printing Office, 1990. OTA-H-405, pp 71-5. <ExternalRef xref="http://www.princeton.edu/~ota/disk2/1990/9044_n.html">Also available online</ExternalRef>. Last accessed May 21, 2015.</Citation><Citation idx="2">Flora Flor•Essence®. Burnaby, Canada: Flora Manufacturing &amp; Distributing Ltd. <ExternalRef xref="http://www.florahealth.com/product_categories_usa.cfm"> Available online</ExternalRef>. Last accessed May 21, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_48"><Title>Summary of the Evidence for Essiac and Flor Essence</Title><Para id="_49">To assist readers in evaluating the results of human/<GlossaryTermRef href="CDR0000044195">clinical studies</GlossaryTermRef> of <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> (CAM) treatments for <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>, a scoring system has been devised that allows studies of individual treatments to be ranked according to the strength of their evidence (i.e., their <GlossaryTermRef href="CDR0000446533">level of evidence</GlossaryTermRef>). Not all studies, however, are given a level of evidence score. To be eligible, a study must:</Para><ItemizedList id="_65" Style="bullet"><ListItem>Evaluate a <GlossaryTermRef href="CDR0000043985">therapeutic</GlossaryTermRef> outcome or outcomes, such as tumor <GlossaryTermRef href="CDR0000044085">response</GlossaryTermRef>, improvement in survival, or carefully measured improvement in <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef>.</ListItem><ListItem>Be reported in a peer-reviewed scientific journal.</ListItem><ListItem>Have its clinical findings published in sufficient detail for a meaningful evaluation to be made.</ListItem></ItemizedList><Para id="_66">Evidence from studies that do not meet these requirements is considered extremely weak. In addition to scoring individual studies, an overall level of evidence assessment is usually made.
</Para><Para id="_50">Because no study of the use of <GlossaryTermRef href="CDR0000446524">Essiac</GlossaryTermRef> or Flor Essence in humans has been reported in a peer-reviewed scientific journal, no level-of-evidence analysis is possible for these mixtures. The data that are available, however, do not support claims that Essiac and Flor Essence can <GlossaryTermRef href="CDR0000446105">detoxify</GlossaryTermRef> the body, strengthen the <GlossaryTermRef href="CDR0000046356">immune system</GlossaryTermRef>, or fight cancer. At this time, evidence does not support the use of either Essiac or Flor Essence in the treatment of cancer patients  outside the context of well-designed <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef>.</Para><Para id="_51">Separate levels-of-evidence scores are assigned to qualifying human studies on the basis of statistical strength of the study design and <GlossaryTermRef href="CDR0000044724">scientific</GlossaryTermRef> strength of the treatment outcomes (i.e., <GlossaryTermRef href="CDR0000346519">endpoints</GlossaryTermRef>) measured. The resulting two scores are then combined to produce an overall score.     For additional information about levels-of-evidence analysis, refer to <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine</SummaryRef>.</Para></SummarySection><SummarySection id="_52"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (05/21/2015)</Title><Para id="_57">The <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_105"><Strong><SummaryRef href="CDR0000301806#_1" url="/about-cancer/treatment/cam/hp/essiac-pdq">Overview</SummaryRef></Strong></Para><Para id="_106">Added <SummaryRef href="CDR0000301806#_104" url="/about-cancer/treatment/cam/hp/essiac-pdq">text</SummaryRef> to note that the information in this summary is no longer being updated and is provided for reference purposes only.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000301806#_AboutThis_1" url="http://www.cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of Essiac/Flor Essence in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Essiac/Flor Essence are:</Para><ItemizedList Style="bullet"><ListItem>John A. Beutler, PhD (National Cancer Institute)</ListItem><ListItem>Wayne Jonas, MD (President and CEO, Samueli Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Cancer Complementary and Alternative Medicine Editorial Board uses a <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Essiac/Flor Essence. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq">http://www.cancer.gov/about-cancer/treatment/cam/hp/essiac-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection><DateFirstPublished>2003-04-23</DateFirstPublished><DateLastModified>2015-05-21</DateLastModified></Summary>
